Nagoya, Japan

Hisataka Maruyama

This inventor holds 1 USPTO granted patent. Top assignee: Mitsui Chemicals, Inc.. Active years: 2023.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hisataka Maruyama: Innovator in Ophthalmic Surgery Training

Introduction

Hisataka Maruyama is a notable inventor based in Nagoya, Japan. He has made significant contributions to the field of ophthalmic surgery through his innovative designs and inventions. His work focuses on enhancing training methods for surgical procedures, particularly in glaucoma surgery.

Latest Patents

Maruyama holds a patent for a device specifically designed for training in ophthalmic surgery. This device addresses the need for effective training tools in glaucoma surgery. The invention includes a simulated-eyeball pedestal with a recess for inserting a simulated eyeball. It also features a mechanism that generates a restoring force to maintain the position of the simulated eyeball, allowing for realistic training experiences.

Career Highlights

Hisataka Maruyama is associated with Mitsui Chemicals, Inc., where he applies his expertise in developing innovative medical training devices. His work has been instrumental in advancing the training methodologies used in ophthalmic surgery, ensuring that future surgeons are well-prepared for their roles.

Collaborations

Maruyama collaborates with talented individuals such as Seiji Omata and Taisuke Masuda. These partnerships enhance the development of innovative solutions in the medical field, particularly in ophthalmology.

Conclusion

Hisataka Maruyama's contributions to ophthalmic surgery training through his patented device exemplify the importance of innovation in medical education. His work continues to impact the training of future surgeons, ensuring better outcomes in patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…